Bristol-Myers Squibb (BMY) Q1 2025 Earnings
Bristol-Myers Squibb reported Q1 2025 revenue of $11.2B (-5.6% YoY), beat analyst consensus of $10.7B by $505.9M. Diluted EPS came in at $1.80, beat the $1.49 consensus by $0.31. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q1 2025 earnings report.
Bristol-Myers Squibb (BMY) reported Q1 2025 earnings on April 24, 2025 before market open.
Bristol-Myers Squibb reported revenue of $11.2B and diluted EPS of $1.80 for Q1 2025.
Revenue beat the consensus estimate of $10.7B by $505.9M. EPS beat the consensus estimate of $1.49 by $0.31.
Compared to the same quarter a year prior, revenue declined 5.6% from $11.9B a year earlier.
You can read the 10-Q periodic report (0000014272-25-000091) directly on SEC EDGAR. The filing index links above go to sec.gov.